Are AstraZeneca plc & Thomas Cook Group plc ‘Screaming Buys’?

Should you buy AstraZeneca plc (LON: AZN) and Thomas Cook Group plc (LON: TCG) right now?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In the long run, all companies encounter highly challenging periods. They can be due to external factors such as a weakening in demand for a particular product or a slowdown in the wider economy. They can also be caused by internal challenges, such as poor planning and a strategy which ultimately leads to disappointing top and bottom line performance.

Either way, it normally has a very negative impact on a company’s share price and, while the effects can be horrific for investors, it also presents a very appealing buying opportunity. That’s because if the company can either adopt a better strategy or the external factors improve, capital gains could prove to be very enticing.

One company which has endured a very tough period is AstraZeneca (LSE: AZN). Its problems have largely been its own making, with the company failing to develop sufficient new drugs and put in place a suitable pipeline to overcome the inevitable loss of patents on key, blockbuster drugs. Furthermore, it also failed to use its cash in the most efficient manner; favouring a share buyback programme ahead of investing in research and development capabilities.

The result has been a severe decline in profitability, with AstraZeneca’s earnings per share expected to be just 62% of their 2011 level when the company reports its 2015 full-year results. However, AstraZeneca appears to now be making all of the right moves through which to mount a successful comeback, with an ambitious acquisition programme breathing new life into the company’s pipeline.

Clearly, it will inevitably take time to post positive profit growth. However, it seems likely to do so over the medium term which makes it current price to earnings (P/E) ratio of 16.1 seem hugely appealing.

Similarly, Thomas Cook (LSE: TCG) has also endured a troubled past, with the company becoming a loss-making entity in the period 2011 to 2014. This had a disastrous impact on the company’s share price, with it falling to a low of 13p in 2012 and there being major concerns about whether it would survive its difficult trading period.

However, now that the economic outlook is improved Thomas Cook is moving from strength to strength. Today’s results show that the company has made its first annual profit in five years despite the negative impact on demand for its holidays caused by the terrorist incidents of recent months. And, with the winter season already being 58% sold, it appears to be well-placed to deliver continued strong performance moving forward.

Looking ahead, Thomas Cook is forecast to increase its earnings by 28% next year which, alongside a P/E ratio of 9.4, puts it on a price to earnings growth (PEG) ratio of just 0.3. This indicates that its shares have very appealing capital gains prospects – especially since the UK and European economies are showing signs of life and are set to benefit from a continued loose monetary policy in future years.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

GSK scientist holding lab syringe
Investing Articles

Why is everyone buying GSK shares?

GSK shares have been outperforming the FTSE 100 in 2026. Paul Summers takes a closer look and asks whether this…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

£10,000 invested in easyJet shares at the start of 2026 is now worth…

Anyone buying easyJet shares will have endured a rough ride since January. Paul Summers wonders whether things could get even…

Read more »

Close-up of a woman holding modern polymer ten, twenty and fifty pound notes.
Investing Articles

5 years ago, £5,000 bought 2,645 Barclays shares. But how many would it buy now?

Despite delivering an impressive return since April 2021, Barclays' shares have lagged the FTSE 100's other banks. James Beard considers…

Read more »

Side of boat fuelled by gas to liquids, advertising Shell GTL Fuel
Investing Articles

5 years ago, £5,000 bought 354 Shell shares. But how many would it buy now?

When it comes to Shell’s numbers, most of them are impressive. And it’s no different when looking at the recent…

Read more »

A rear view of a female in a bright yellow coat walking along the historic street known as The Shambles in York, UK which is a popular tourist destination in this Yorkshire city.
Investing Articles

I asked ChatGPT if I should buy Aviva, Diageo or BAE Systems stock and it said…

Aviva, Diageo and BAE Systems shares are popular FTSE 100 picks. But which of the three does ChatGPT like the…

Read more »

Tesla car at super charger station
Investing Articles

SpaceX’s IPO threatens to leave the Tesla share price on the forecourt

As Elon Musk starts fuelling the engines for a SpaceX IPO, could the Tesla share price get left in the…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
US Stock

A once-in-a-decade chance to buy software stocks?

Michael Burry thinks now is the time to think about buying falling tech stocks. But it might depend on which…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Here’s how a £20k ISA could generate a £1,000 weekly second income

Drip-feeding money into a Stocks and Shares ISA can put you on track to a four-figure second income. Royston Wild…

Read more »